Sinovac Biotech Ltd (SVA) — Capital Reinvestment Ratio

Latest as of December 2023: 0.36x

Sinovac Biotech Ltd (SVA) has a Capital Reinvestment Ratio of 0.36x as of December 2023, meaning it reinvests 0% of its operating cash flow ($146.01 Million) in capital expenditures ($52.75 Million). See net asset quality index of Sinovac Biotech Ltd to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.36x
Capex / Operating Cash Flow

Operating Cash Flow

$146.01 Million
USD

Capital Expenditures

$52.75 Million
USD

Data as of

Dec 2023
Most recent filing

Sinovac Biotech Ltd Capital Reinvestment Ratio (2007–2023)

This chart tracks Sinovac Biotech Ltd's Capital Reinvestment Ratio across 12 annual periods. Check Sinovac Biotech Ltd (SVA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Sinovac Biotech Ltd (2007–2023)

Year-by-year Capital Reinvestment Ratio for Sinovac Biotech Ltd from 2007 to 2023. For live market cap and broader valuation context, see market cap of Sinovac Biotech Ltd.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 1.37x $106.02 Million $145.69 Million ▲ +2830.3%
2021 0.05x $15.35 Billion $719.98 Million ▼ -82.4%
2020 0.27x $479.31 Million $127.65 Million ▼ -2.1%
2019 0.27x $39.07 Million $10.63 Million ▼ -61.5%
2018 0.71x $7.94 Million $5.61 Million ▲ +254.4%
2017 0.20x $59.76 Million $11.91 Million ▼ -84.2%
2015 1.26x $4.21 Million $5.30 Million ▲ +36.7%
2013 0.92x $5.58 Million $5.13 Million ▼ -17.0%
2011 1.11x $13.94 Million $15.46 Million ▲ +1142.9%
2009 0.09x $48.41 Million $4.32 Million ▼ -76.4%
2008 0.38x $10.50 Million $3.98 Million ▼ -33.8%
2007 0.57x $4.32 Million $2.47 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow